Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance
Vifor Pharma Group recorded strong financial and operational performance in 2019 by focusing on its three strategic growth drivers while continuing to invest in its pipeline. The company exceeded its raised guidance for full-year 2019 on both net sales and EBITDA.
FINANCIAL PERFORMANCE: STRONG SALES AND PROFIT GROWTH CONTINUES
Net sales of CHF 1,887.2 million, up 18.5%
EBITDA of CHF 540.0 million, up 37.9%
Core EPS of C...